Clinical Trial Update: Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma [NA]

View source ↗

Summary

A clinical trial is evaluating intravenous autologous CD19 CAR-T cells for relapsed or refractory lymphoblastic leukemia and relapsed/refractory multiple myelom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Or Refractory Multiple Myeloma

Drugs mentioned

• Autologous CD19 CAR-T Cells (CD19 CAR-T cells)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM) | NA | Status: RECRUITING